CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 72 enrolled
Drug / intervention
Eslicarbazepine Acetatedrug
Likely dose
Eslicarbazepine Acetate 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01422720
NCT01422720Phase 3Completed
CompareCT.gov

Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients

Bial - Portela C S.A.·interventional·Posted Aug 24, 2011·Updated Aug 7, 2017

In Brief

A Phase 3 clinical trial evaluating Eslicarbazepine Acetate for Epilepsy. Completed, enrolled 72 participants across 48 sites in 10 countries.

Detailed Summary

This is an open Label study to investigate the safety and efficacy of eslicarbazepine acetate as adjunctive therapy for partial seizures in elderly patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesAustria, Bulgaria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania, Spain
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 24, 2011
Enrollment StartApr 1, 2010
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 14.9 years ago

Interventions

Eslicarbazepine Acetatedrug

ESL tablets (800 mg) QD